Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases
The risk of dying from a pulmonary embolism (PE) is estimated to be about 30% if inotropic support is required and no cardiopulmonary arrest occurs. Fibrinolysis in massive PE is regarded as a life-saving intervention, unless there is a high risk of bleeding following the use of the fibrinolytic the...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982239/ |
| id |
pubmed-3982239 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-39822392014-04-14 Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases Kim, Hye-Jin Koo, So-My Ham, Nam-Suk Kim, Ki-Up Uh, Soo-taek Kim, Yang-Ki Case Report The risk of dying from a pulmonary embolism (PE) is estimated to be about 30% if inotropic support is required and no cardiopulmonary arrest occurs. Fibrinolysis in massive PE is regarded as a life-saving intervention, unless there is a high risk of bleeding following the use of the fibrinolytic therapy. Rivaroxaban is an oral factor Xa inhibitor, however its anticoagulation effects before or after administration of fibrinolytics in massive PE are still unknown. Two patents were admitted: 61-year-old woman with repeated syncope, and a 73-year-old woman was admitted with dyspnea and poor oral intake. Systemic arterial hypotension with radiologic confirmation led to a diagnosis of massive PE in both patients. Rivaroxaban was administered before in one, and after firbrinolytic therapy in the other. One showed similar efficacy of rivaroxaban with currently used anticoagulants after successful fibrinolysis, and the other one without antecedent administration of the fibrinolytic agent showed unfavorable efficacy of rivaroxaban. The Korean Academy of Tuberculosis and Respiratory Diseases 2014-03 2014-03-29 /pmc/articles/PMC3982239/ /pubmed/24734100 http://dx.doi.org/10.4046/trd.2014.76.3.127 Text en Copyright©2014. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Kim, Hye-Jin Koo, So-My Ham, Nam-Suk Kim, Ki-Up Uh, Soo-taek Kim, Yang-Ki |
| spellingShingle |
Kim, Hye-Jin Koo, So-My Ham, Nam-Suk Kim, Ki-Up Uh, Soo-taek Kim, Yang-Ki Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases |
| author_facet |
Kim, Hye-Jin Koo, So-My Ham, Nam-Suk Kim, Ki-Up Uh, Soo-taek Kim, Yang-Ki |
| author_sort |
Kim, Hye-Jin |
| title |
Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases |
| title_short |
Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases |
| title_full |
Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases |
| title_fullStr |
Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases |
| title_full_unstemmed |
Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases |
| title_sort |
effect of rivaroxaban on fibrinolytic therapy in massive pulmonary embolism: two cases |
| description |
The risk of dying from a pulmonary embolism (PE) is estimated to be about 30% if inotropic support is required and no cardiopulmonary arrest occurs. Fibrinolysis in massive PE is regarded as a life-saving intervention, unless there is a high risk of bleeding following the use of the fibrinolytic therapy. Rivaroxaban is an oral factor Xa inhibitor, however its anticoagulation effects before or after administration of fibrinolytics in massive PE are still unknown. Two patents were admitted: 61-year-old woman with repeated syncope, and a 73-year-old woman was admitted with dyspnea and poor oral intake. Systemic arterial hypotension with radiologic confirmation led to a diagnosis of massive PE in both patients. Rivaroxaban was administered before in one, and after firbrinolytic therapy in the other. One showed similar efficacy of rivaroxaban with currently used anticoagulants after successful fibrinolysis, and the other one without antecedent administration of the fibrinolytic agent showed unfavorable efficacy of rivaroxaban. |
| publisher |
The Korean Academy of Tuberculosis and Respiratory Diseases |
| publishDate |
2014 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982239/ |
| _version_ |
1612076591480832000 |